Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.

Krovi SA, Gallovic MD, Keller AM, Bhat M, Tiet P, Chen N, Collier MA, Gurysh EG, Pino EN, Johnson MM, Shamim Hasan Zahid M, Cottrell ML, Pirone JR, Kashuba AD, Kwiek JJ, Bachelder EM, Ainslie KM.

Int J Pharm. 2018 Dec 1;552(1-2):371-377. doi: 10.1016/j.ijpharm.2018.10.017. Epub 2018 Oct 8.

2.

Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.

Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ.

Pharm Res. 2017 Dec;34(12):2749-2755. doi: 10.1007/s11095-017-2255-7. Epub 2017 Sep 13. Erratum in: Pharm Res. 2019 May 20;36(7):108.

3.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, Porter D, Shao Y, Myers M, Ting L, SenGupta D, Quirk E, Rhee MS.

Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.

PMID:
27765666
4.

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

Imaz A, Niubó J, Kashuba AD, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczer D.

HIV Med. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1.

5.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

Kulkarni R, Hodder SL, Cao H, Chang S, Miller MD, White KL.

HIV Clin Trials. 2017 Jul;18(4):164-173. doi: 10.1080/15284336.2017.1370059.

6.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.

Antivir Ther. 2015;20(3):317-27. doi: 10.3851/IMP2885. Epub 2014 Oct 16.

PMID:
25321623
7.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.

HIV Clin Trials. 2014 Sep-Oct;15(5):218-30. doi: 10.1310/hct1505-218.

PMID:
25350960
8.

Long-acting slow effective release antiretroviral therapy.

Edagwa B, McMillan J, Sillman B, Gendelman HE.

Expert Opin Drug Deliv. 2017 Nov;14(11):1281-1291. doi: 10.1080/17425247.2017.1288212. Epub 2017 Feb 6. Review.

9.

Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.

Biagi M, Badowski ME, Chiampas T, Young J, Patel M, Vaughn P.

Int J STD AIDS. 2017 Jul;28(8):766-772. doi: 10.1177/0956462416666440. Epub 2016 Sep 1.

PMID:
27587601
10.

Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.

Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM Jr, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.

PLoS Med. 2018 Sep 28;15(9):e1002655. doi: 10.1371/journal.pmed.1002655. eCollection 2018 Sep.

11.

Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.

Prathipati PK, Mandal S, Destache CJ.

J Pharm Biomed Anal. 2016 Sep 10;129:473-481. doi: 10.1016/j.jpba.2016.07.040. Epub 2016 Jul 26.

12.

Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.

Hobson JJ, Al-Khouja A, Curley P, Meyers D, Flexner C, Siccardi M, Owen A, Meyers CF, Rannard SP.

Nat Commun. 2019 Mar 29;10(1):1413. doi: 10.1038/s41467-019-09354-z.

13.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
14.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team.

Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
15.

Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study.

Mandal S, Kang G, Prathipati PK, Fan W, Li Q, Destache CJ.

Antiviral Res. 2018 Aug;156:85-91. doi: 10.1016/j.antiviral.2018.06.005. Epub 2018 Jun 6.

PMID:
29885378
16.

Development and characterization of a long-acting nanoformulated abacavir prodrug.

Singh D, McMillan J, Hilaire J, Gautam N, Palandri D, Alnouti Y, Gendelman HE, Edagwa B.

Nanomedicine (Lond). 2016 Aug;11(15):1913-27. doi: 10.2217/nnm-2016-0164. Epub 2016 Jul 26.

17.

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.

Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, Szlachetka A, Lamberty B, Fox HS, Poluektova L, Gorantla S, McMillan J, Gautam N, Mosley RL, Alnouti Y, Edagwa B, Gendelman HE.

Biomaterials. 2018 Jan;151:53-65. doi: 10.1016/j.biomaterials.2017.10.023. Epub 2017 Oct 15.

18.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.

Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):209-213. doi: 10.1097/QAI.0000000000001663.

20.

Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.

Mohideen M, Quijano E, Song E, Deng Y, Panse G, Zhang W, Clark MR, Saltzman WM.

Biomaterials. 2017 Nov;144:144-154. doi: 10.1016/j.biomaterials.2017.08.029. Epub 2017 Aug 15.

Supplemental Content

Support Center